Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Background Many patients with psoriatic arthritis do not reach minimal disease activity (MDA) on methotrexate alone. This phase 4 open-label study aimed to compare attainment of MDA following introduction of adalimumab with methotrexate escalation in patients with psoriatic arthritis who do not reac...

Full description

Bibliographic Details
Main Authors:	Coates, LC, Tillett, W, D’Agostino, MA, Rahman, P, Behrens, F, McDearmon-Blondell, EL, Bu, X, Chen, L, Kapoor, M, Conaghan, PG, Mease, P
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
by: Kavanaugh, A, et al.
Published: (2005)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
by: Choy, E, et al.
Published: (2007)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
by: Landewé, R, et al.
Published: (2019)

The role of ultrasound in psoriatic arthritis — do we need a score?
by: D'Agostino, MA, et al.
Published: (2019)

Should methotrexate have any place in the treatment of psoriatic arthritis?
by: Ye, W, et al.
Published: (2019)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
by: Nash, P, et al.
Published: (2020)

Remission in psoriatic arthritis—where are we now?
by: Coates, L, et al.
Published: (2017)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
by: Mease, P, et al.
Published: (2018)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
by: Coates, L, et al.
Published: (2019)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)

Performance and predictors of minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab
by: Coates, LC, et al.
Published: (2020)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
by: Gladman, DD, et al.
Published: (2018)

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
by: Mysler, E, et al.
Published: (2021)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Considerations for the definition of remission criteria in psoriatic arthritis
by: Mease, P, et al.
Published: (2017)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

What should be the primary target of "treat to target" in psoriatic arthritis?
by: Coates, LC, et al.
Published: (2018)

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
by: Merola, JF, et al.
Published: (2022)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
by: Taylor, P, et al.
Published: (2019)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
by: Taylor, P, et al.
Published: (2017)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
by: Coates, L, et al.
Published: (2022)

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
by: De Marco, G, et al.
Published: (2017)

The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: a call for consensus
by: Tillett, W, et al.
Published: (2022)

Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel
by: Coates, LC, et al.
Published: (2024)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
by: Coates, L, et al.
Published: (2017)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
by: Mease, PJ, et al.
Published: (2020)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2021)

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
by: Siebert, S, et al.
Published: (2024)

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis
by: Siebert, S, et al.
Published: (2024)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
by: Mathew, A, et al.
Published: (2016)

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative
by: Antony, A, et al.
Published: (2021)

The State of the Art - Psoriatic Arthritis outcome assessment in clinical trials and daily practice
by: Day, J, et al.
Published: (2022)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
by: Keystone, E, et al.
Published: (2015)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
by: O'Dwyer, J, et al.
Published: (2018)